The funding will accelerate clinical development and global market introduction of breakthrough nanorobotic solutions for dental conditions affecting billions worldwide
Theranautilus, a pioneering deep-tech company developing nanorobotic solutions for healthcare, has raised $1.2 million in seed funding. The round led by pi Ventures also saw participation from Golden Sparrow Ventures and angel investors including Abhishek Goyal, Founder and CEO of Tracxn, and Lalit Keshre, CEO of Groww.
With the recently raised funding, the company aims to become the first company globally to commercialise nanorobotics-based medical devices, initially targeting dental care applications. Additionally, the funds will be utilised to develop Theranautilus's go-to-market strategy and to advance its efforts in extending innovative technology beyond dental applications.
The technology has been extensively tested in animals and the company aims to launch the first-of-its-kind human trials for a nanorobotic medical device in 2025.
Additionally, the company aims to develop and commercialise precision theranostics-based interventions to manage cancer therapy and other diseases.
Dr Shanmukh Srinivas, Co-Founder and CEO, Theranautilus, says, "What sets our technology apart is its ability to address health challenges at a microscopic level with unprecedented precision. With this funding, we're not just developing a product, we're introducing a new paradigm in healthcare where nanorobots can navigate and perform different therapeutic and diagnostic procedures within the human body. Our initial focus on dental care represents the first step in what we envision as a revolution in medical treatment. "
The company is also exploring partnerships with global healthcare corporations, dental care providers and medical institutions to expand the reach of its innovative technology.
Sohil Bhagat, Principal, pi Ventures said, “The founding team at Thernautilus is well positioned to transform groundbreaking science into scalable, impactful solutions. We look forward to working with them and supporting their journey in building products that we believe will redefine healthcare on a global scale. Their treatment for dental hypersensitivity could revolutionise a multibillion-dollar global industry and set new healthcare standards. Furthermore, their revolutionary adaptable nanotechnology platform promises to open up new avenues for minimally invasive therapy across medical sectors."
